Q2 Galleri® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively, for the First Half of the Year NHS-Galleri and PATHFINDER 2 Study Results Presented at 2026 ASCO Annual Meeting Demonstrated Consistent Strong Performance and […]
GRAIL Reports Second Quarter 2026 Financial Results Read More »
The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer 71% of the New Cancers Detected by the Galleri Test Were in Stages I-III MENLO PARK, Calif., May 31, 2026 – GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is
No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round Annual Galleri® Blood Test Reduced Stage IV Diagnoses of 12 Prespecified Cancers by 22% and 26% in the Second and Third Screening Rounds, Respectively Galleri Increased Cancer Detection Rate by Four-Fold When Added to
Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within Their Existing Patient Portal Collaboration With Epic Will Allow Clinicians to Seamlessly Order the Galleri Multi-Cancer Early Detection Test at the Point of Care MENLO PARK, Calif. — April 7, 2026 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer
FDA Submission Marks a Pivotal Milestone in Advancing Early Cancer Detection, Addressing Unmet Needs in Cancer Screening MENLO PARK, Calif. – Jan. 29, 2026 – GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the submission of the final module of the Premarket
